Enanta Pharmaceuticals (ENTA) EBITDA Margin Growth (1y) (2013 - 2026)
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) EBITDA Margin Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -1,651.00 |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 29,091.00 |
| 10 | Enanta Pharmaceuticals | 405.22 Mn | 215.72 Mn | - | -1,687.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,687.00 |
| Mar 31, 2026 | 9,525.00 |
| Dec 31, 2025 | 7,837.00 |
| Sep 30, 2025 | 8,282.00 |
| Jun 30, 2025 | 3,142.00 |
| Mar 31, 2025 | 2,781.00 |
| Dec 31, 2024 | 5,496.00 |
| Sep 30, 2024 | -4,048.00 |
| Jun 30, 2024 | 5,975.00 |
| Mar 31, 2024 | 2,957.00 |
| Dec 31, 2023 | -6,652.00 |
| Sep 30, 2023 | -3,077.00 |
| Jun 30, 2023 | -2,728.00 |
| Mar 31, 2023 | -4,085.00 |
| Dec 31, 2022 | -1,727.00 |
| Sep 30, 2022 | 993.00 |
| Jun 30, 2022 | -1,053.00 |
| Mar 31, 2022 | -3,332.00 |
| Dec 31, 2021 | -7,124.00 |
| Sep 30, 2021 | -5,935.00 |